China Earnings Overview: Sanofi’s OTC Slowdown, Bayer’s Glucobay Legendary Success
This article was originally published in PharmAsia News
Executive Summary
With China the main engine of growth for multinational drug firms in emerging markets, PharmAsia News takes a closer look at companies’ China earnings, finding some strong Q3 sales figures, but slowdowns for others.